scPharmaceuticals Inc.

NasdaqGS:SCPH Rapport sur les actions

Capitalisation boursière : US$268.7m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

scPharmaceuticals Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

John Tucker

Directeur général

US$1.8m

Rémunération totale

Pourcentage du salaire du PDG32.8%
Durée du mandat du directeur général7.6yrs
Propriété du PDG0.2%
Durée moyenne d'occupation des postes de directionpas de données
Durée moyenne du mandat des membres du conseil d'administration6.8yrs

Mises à jour récentes de la gestion

Recent updates

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Oct 10

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Aug 26

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Mar 09
Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Nov 24
How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Analyse de la rémunération des PDG

Comment la rémunération de John Tucker a-t-elle évolué par rapport aux bénéfices de scPharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$61m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023US$2mUS$604k

-US$55m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$580k

-US$37m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$550k

-US$28m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$2mUS$531k

-US$32m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$514k

-US$33m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$1mUS$494k

-US$29m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$2mUS$380k

-US$24m

Rémunération vs marché: La rémunération totale de John ($USD 1.84M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 1.54M ).

Rémunération et revenus: La rémunération de John a augmenté alors que l'entreprise n'est pas rentable.


PDG

John Tucker (61 yo)

7.6yrs

Titularisation

US$1,838,662

Compensation

Mr. John H. Tucker has been the Chief Executive Officer and President of scPharmaceuticals Inc. (alternate name: scPharmaceuticals LLC) since January 30, 2017 and serves as its Principal Executive Officer...


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
John Tucker
President8.6yrsUS$1.84m0.18%
$ 486.8k
Leonard Schaeffer
Independent Director9.7yrsUS$184.55k0.11%
$ 308.5k
Jack Khattar
Independent Chairman of the Board8.2yrsUS$227.05k0.010%
$ 26.8k
Mette Agger
Independent Director10.4yrsUS$189.55k0%
$ 0
Klaus Veitinger
Independent Director6.8yrsUS$187.05k0%
$ 0
Marvin Konstam
Member of Scientific Advisory Boardno datapas de donnéespas de données
William Abraham
Independent Director3.5yrsUS$182.05k0%
$ 0
Minnie Baylor-Henry
Independent Director6.1yrsUS$187.05k0%
$ 0
Frederick Hudson
Independent Director6.2yrsUS$197.05k0%
$ 0
Sara Bonstein
Independent Director4.1yrsUS$187.05k0%
$ 0
G. Felker
Member of Scientific Advisory Boardno datapas de donnéespas de données
Dan Bensimhon
Member of Scientific Advisory Boardno datapas de donnéespas de données

6.8yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de SCPH sont considérés comme expérimentés (ancienneté moyenne 6.8 ans).